ScreenerHero

PTHSPelthos Therapeutics Inc. Common Stock

AMEX · US · Healthcare · Biotechnology · pelthos.com
25.51USD-1.20%Mkt Cap: 97.66M $P/E: —

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagio…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap97.66M $
Enterprise Value146.58M $
Revenue (TTM)43.30M $
Gross Profit7.43M $
Net Income (TTM)-43.32M $
Revenue/Share13.21 USD
Last Price25.51 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees92
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.49
PEG—
EV/EBITDA—
EV/Revenue3.38
P/S2.26
P/B-60.17
EPS (TTM)-28.63
EPS (Forward)-5.68
52W Range
18.1938% of range37.50
52W High37.50 USD
52W Low18.19 USD
Profitability
Gross Margin44.24%
Oper. Margin-101.41%
EBITDA Margin0.00%
Profit Margin-257.93%
ROE-111.41%
ROA-33.22%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.59M $
CapEx (TTM)8.00M $
FCF Margin-84.46%
FCF Yield-37.45%
Net Debt48.92M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.90
Current Ratio1.98
Quick Ratio1.21
Book Value/Sh-0.4240 USD
Cash/Share6.319 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJul 2, 2025
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)53.14 USD
Upside (mean)+108.3%
Target Range45.00 USD – 64.00 USD
$45.00+108.3% to mean$64.00
# Analysts7
Ownership
Shares Out.3.83M
Float1.42M
Insiders49.31%
Institutions42.26%
Short Interest
Short Ratio1.0d
Short % Float4.06%
Short % Out.2.00%
Shares Short69.53K
Short (prev mo.)27.79K
Technical
SMA 5027.38 (-6.8%)
SMA 20025.88 (-1.4%)
Beta3.13
S&P 52W Chg19.18%
Avg Vol (30d)78.89K
Avg Vol (10d)26.42K
Technical Indicators
RSI (14)42.2
MACD-0.1244
MACD Signal0.1909
MACD Hist.-0.3153
BB Upper30.16 USD
BB Middle27.52 USD
BB Lower24.88 USD
BB Width19.17%
ATR (14)2.071 USD
Vol Ratio (20d)0.22x